Log In
BCIQ
Print this Print this
 

XmAb5871

  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionHumanized mAb targeting CD19 and Fc gamma receptor IIb (FCGR2B; CD32B)
Molecular Target CD19 ; Fc gamma receptor IIb (FCGR2B) (CD32B)
Mechanism of ActionBinds CD19; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$500.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/28/2014

0

0

0

01/06/2011

$500.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today